Endothelial to mesenchymal transition (EndMT) is a process whereby an endothelial cell undergoes a series of molecular events that lead to a change in phenotype toward a mesenchymal cell (e.g., myofibroblast, smooth muscle cell). EndMT plays a fundamental role during development, and mounting evidence indicates that EndMT is involved in adult cardiovascular diseases (CVDs), including atherosclerosis, pulmonary hypertension, valvular disease, and fibroelastosis.
T he endothelium is arguably one of the largest organ systems, and data continue to emerge regarding its heterogeneity and the many complex functions that it performs. Importantly, substantial evidence has implicated "endothelial dysfunction" as contributing to a range of cardiovascular diseases (CVDs). However, the broader programs whereby "endothelial dysfunction" leads to CVD pathogenesis have been challenging to define.
Here, we review the rapidly expanding published data implicating the endothelial to mesenchymal transition (EndMT) as a common and potentially disease-causal biological program in CVD, highlighting the gaps in knowledge and therapeutic opportunities (Central Illustration).
To place EndMT in context, it is important to first consider epithelial to mesenchymal transition (EMT).
Our understanding of EMT has its origins in seminal studies of embryonic development from the 1920s and the work of Johannes Holtfreter (1). However, it
was not until the 1960s that chick embryo studies conducted by Elizabeth Hay led to the understanding that epithelial cells can undergo a "transformation"
and give rise to embryonic mesoderm (2) . It was later appreciated that EMT is reversible (mesenchymal to epithelial transition [MET] ), and gradually the term "transition" has replaced "transformation." Given these initial studies, it is not surprising that a great deal is known about the indispensable roles of EMT/ MET during embryonic development (which we previously reviewed from a cardiovascular perspective [3] ). However, an equally impressive body of research also attests to the importance of EMT/MET during adult life. While many examples exist, such as the role played by EMT in organ fibrosis (4), perhaps the most relevant from a translational perspective is the role of EMT in cancer (5) . While EMT is implicated in multiple aspects of cancer, and in particular epithelial tumor metastasis (5) , it is notable that multiple targeted therapies aiming to inhibit EMT in cancer are already undergoing clinical evaluation (5) . Furthermore, the inhibition of EMT is a partial effect of several U.S. Food and Drug Administration-approved chemotherapeutic agents that are already in use (6) .
Although a vast amount has been learned about EMT/MET, our knowledge of EndMT is far more rudimentary. However, the endothelium is a specialized subtype of epithelium, and therefore, as highlighted throughout this review, it has been possible to extend some of the prior knowledge regarding EMT to EndMT.
A FUNCTIONAL AND MOLECULAR

DEFINITION OF EndMT
Conceptually, EndMT involves a transition from an endothelial to a mesenchymal-like cellular state. However, at a molecular level, there are no agreed upon criteria for defining EndMT. This is rapidly becoming a hindrance, as there is no standardization and often little cross-comparability among data from different model systems and laboratories. Moreover, with respect to both development and CVD, the field must take account of endothelial cellular origins and their significant heterogeneity when considering formal EndMT definitions. Here, we review the current methods and systems used to study and define
EndMT.
IN VITRO EndMT MODELS. EndMT is readily studied using in vitro cell culture systems. in vivo (9) . Such mice are able to activate Crerecombinase, which can be placed under the control of an endothelial-specific gene (e.g., VE-Cadherin).
Cre activation is used to trigger defined genetic events, like the expression of a fluorescent marker protein that can be used to track ECs. With careful selection, Cre-lox systems can achieve permanent fluorescent marking of ECs, such that they continue to exhibit the fluorescent signal even if they undergo EndMT and suppress endothelial gene/protein expression. Alternatively, EC-specific Cre mouse strains can be crossed to "floxed" strains, where Cre activation leads to the deletion of a gene of interest.
EC-specific Cre-lox gene deletion strategies can be used to selectively delete genes of interest that regulate EndMT, and thus, the effects of these genes and EndMT on differing biological processes can be determined (10, 11) .
As a further method for studying EndMT in vivo (and also in vitro), high-throughput RNA sequencing, of bulk or single cell preparations, is a powerful tool for studying the cellular transcriptome, whereby endothelial and mesenchymal gene expression patterns can be profiled to define the extent of EndMT.
For example, bulk RNA deep sequencing of purified murine cells showed that following myocardial infarction or tissue hypoxia, ECs undergo clonal expansion and express mesenchymal genes such as SM22a in vivo (12) . In addition, due to its potential to resolve EC signatures while concurrently showing mesenchymal gene up-regulation at the single-cell level, it is anticipated that single-cell RNA sequencing will be another useful tool for studying EndMT in vivo in human samples. Furthermore, RNA sequencing holds promise for providing insights on EC plasticity, which is the ability of an EC to switch its identity, including to additional phenotypes other than mesenchymal cells and also, having changed identity, to revert back to an EC state (see review [13] ).
CELLULAR AND MOLECULAR ANALYSIS OF EndMT.
A diverse selection of readouts has been used to Table 1) . However, yet again, no standardization exists. Indeed, reaching a consensus on these functional cellular aspects may be challenging, because certain EndMTrelated phenotypic features may be important in specific contexts, but irrelevant or even opposing in others. For example, reduced tubule formation (i.e., angiogenesis) has been associated with EndMT (14, 15) , but as an apparent paradox, at least partial EndMT is necessary for angiogenesis (16). Highlighting this paradox at a molecular level, the transcription factor SNAI2 is expressed in angiogenic ECs and mediates angiogenesis (16), but SNAI2 is also a key mediator of EndMT (11) . A full reconciliation of these functional aspects will likely remain challenging until more is understood about EndMT as a whole.
EndMT IN CARDIAC DEVELOPMENT
Heart progenitor cells arise within the embryo from newly formed mesoderm that originates from the primitive streak. After heart tube formation, the endocardium and endothelium of the great vessels are created by vasculogenesis (17-19), whereby vessels form de novo from endothelial progenitors. The endocardium likely has heterogeneous origins, arising from endocardial-myocardial heart field progenitors (17, 18, [20] [21] [22] , and also cells that migrate in from the yolk sac mesoderm (an extraembryonic tissue) (19) . Some endocardial cells express markers of hemogenic endothelium, perhaps reflecting their origins from yolk sac hemangioblasts (a common progenitor of blood and vessels) (19) and the activation of the hematopoietic program within embryonic endothelium (23) .
As the heart develops, the endocardium retains remarkable cellular plasticity. For example, the endocardium associated with the forming ventricles undergoes a process that resembles angiogenic sprouting in developing vascular beds (24) , leading to the formation of endocardial domes which, together with myocardium and extracellular matrix (ECM), define the morphological units of trabeculation. The endothelium of the coronary arteries and veins is also formed by sprouting, in this case from the sinus venosus endocardium into the myocardium (25) . This process leads to formation of an endothelial plexus within the subepicardial ECM, which then extends deeper into the myocardial walls (26, 27) . Developmental patterning of the coronary vessels may then be supplemented by adaptive angiogenesis initiated by sprouting of endocardium from the intertrabecular crypts into the myocardial wall, driven by hypoxia (27) (28) (29) (30) . Trabecular endocardium also contributes to the coronary arterial tree postnatally, as the outer "compact" myocardial layer undergoes expansion (29) . Blood islands form on the ventral surface of the heart through a budding process, and these contain an endothelium that is also derived from the endocardium (27) . Blood island endothelium expresses hemogenic markers (31) , suggesting that the blood cells found within these islands are derived from the endothelium (and hence endocardium). In ECs, TGF-b classically signals via TGF-bR2 (a type II receptor component) and AKL1 or ALK5 (type I receptor complexes). Receptor complexes combine on the cell surface and comprise 2 type I and 2 type II components. TGF-bR2 phosphorylates (activates) type I components, which then propagate the signal intracellularly via activation (phosphorylation; pSMAD) of SMAD 1, 2, 3, 5, or 8. Activated SMAD proteins form complexes that include the common mediator SMAD4, and which may be inhibited by SMAD6 or SMAD7. SMAD complexes shuttle to the nucleus, where they interact with coactivators, corepressors, and additional transcription factors, the latter including key
EndMT gatekeepers SNAI1/2, ZEB1/2, KLF4, TCF3, and TWIST. These interactions culminate in chromatin rearrangements and transcription factor binding to endothelial, mesenchymal, and other gene promoter regions that ultimately bring about EndMT. Abbreviations as in Figure 1 .
Kovacic et al.
EndMT in Cardiovascular Disease Supporting these findings, Mahmoud et al. (109) showed that low, oscillatory shear stress promotes
EndMT, whereas high shear stress is protective. In this case, low-shear related EndMT was under the control of SNAI1 (109) and TWIST1 (110), whereas costaining was again suggestive of EndMT in human atherosclerotic plaques (109) . Importantly, the link between EndMT and disturbed flow indirectly suggests that EndMT may be causal for atherosclerosis.
As a sidebar, but also indirectly suggesting that
EndMT may be causal for atherosclerosis, it was recently shown that atheroprotective high-density lipoproteins inhibit EndMT (111) .
Two studies have used Cre-lox mouse models to study EndMT in atherosclerosis, with both showing that EndMT plays an important role. Of these, Evrard et al. (8) showed that the predominant EndMTderived cell population in atherosclerosis is fibroblast-like cells, with a lesser contribution to smooth muscle-like cells ( Figure 6 ). Overall,
EndMT-derived cells comprised almost one-half of the fibroblast population in advanced atherosclerotic lesions. In addition, they showed that EndMT is Confocal microscopy of thoracic aortic sections from tamoxifen-induced end.SclCreER T ;R26RstopYfp;ApoE -/-mice after Western diet feeding.
In this model of advanced atherosclerosis, ECs are permanently marked using a Cre-lox system such that ECs, and all EC-derived cells, permanently express yellow fluorescence protein (Yfp). Staining for Ve-Cadherin is in red, with staining for fibroblast activation protein (Fap), a fibroblast marker, in white. DAPI nuclear staining is in blue. Novel mouse models that mimic human EFE now permit studies of the origin of EFE tissues and their mechanisms of formation (127, 128) . As discussed, during development, the endocardium undergoes
EndMT to form the cardiac valves and septa ( Figure 1 ). EndMT is important in vein graft remodeling and neointimal formation, which is the maladaptive smooth muscle cell hyperplasia that arises after a vein is exposed to arterial pressure. Specifically, with the adaptation to arterial pressure, they observed that w50% of neointimal cells were EndMT-derived (11).
EndMT-derived cells were found to be typical syn- A potential explanation may lie in the fact that during EndMT in the adult, cells with a fully mature mesenchymal phenotype may be rarely achieved (8) .
In EndMT was first identified in PAH based on in situ analyses of endothelial and mesenchymal markers, as EndMT ¼ endothelial to mesenchymal transition. 
Lack of a robust functional and molecular definition of EndMT
The lack of a functional and molecular definition of EndMT is fostering scientific confusion, hampering research and interpretation, limiting comparability of data, and facilitating the publication of studies with suboptimal endpoints.
Research teams should work together to achieve a functional and molecular definition in the near term. This will require sharing of data, pooling and combined analyses of highthroughput datasets (i.e., RNA sequencing, proteomics), and consensus agreement on definitions. This will be an ongoing process that will need refinement as further data and knowledge emerge. Embedded within this task is the understanding of additional molecular issues such as the reversibility of EndMT, or whether it is a clonal phenomenon.
Lack of understanding of the contribution of EndMT to disease causation (vs. being a disease association or epiphenomenon)
This problem is challenging to address in the human context, but genetic mouse models are well-suited to this task. However, these studies require significant resources and meticulous scientific approaches that must be relevant to EndMT in human pathology.
We propose extensive, well-designed, and meticulously conducted genetic mouse studies, with validation and reproducibility achieved among collaborating laboratories.
Lack of robust human data on EndMT Although mouse studies are the most effective model system for rigorous proof of concept and for demonstrating causality, findings must be validated (ideally) in larger animals and (absolutely) in humans. Furthermore, some critical questions that drive our interest in EndMT, such as the role of EndMT in plaque erosion, can only be tackled in humans as there are no true animal models.
We propose detailed human studies using explanted and surplus surgical tissues from relevant disease states, with the application of cutting-edge techniques such as single-cell RNA sequencing to explore the contribution and extent of EndMT. Cross-validation among collaborating laboratories of key findings will be essential.
Lack of translational proof of concept Few studies have attempted to manipulate EndMT in larger animals (122) (123) (124) . Although large animal translational proof-of-concept studies are clearly necessary, they require extensive resources and clear scientific objectives. A critical consideration is the existence of a suitable model, and whether regulatory authorities would require large animal studies before clinical trials could commence. Moreover, this may be disease-specific and context-specific, because EndMT appears relevant across a range of CVDs.
Consortia should be formed with a view to prioritizing EndMT targets in disease states amenable to large animal models, with a view to systematically studying the utility of manipulating EndMT for therapeutic gain. It will be essential to engage with regulatory authorities to assess need and appropriate nature of such models in the functional disease context.
well as an intervention study using rapamycin that A growing list of other CVDs are also associated with EndMT. Although in some cases the evidence is perhaps not as robust as the studies and diseases mentioned previously, these are summarized in Table 2 .
CONCLUSIONS AND FUTURE DIRECTIONS
EndMT is involved in numerous CVDs, which collectively are a major cause of global morbidity and mortality. Hence, the manipulation of EndMT for therapeutic gain is a tantalizing prospect. Nevertheless, a number of obstacles remain to be overcome before the full therapeutic potential of manipulating
EndMT can be realized, as described in Table 3 . Kingdom. E-mail: Andy.Baker@ed.ac.uk, Twitter: @EdinUniCVS.
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